AU628913B2 - Pyrazolopyridine compound and processes for preparation thereof - Google Patents

Pyrazolopyridine compound and processes for preparation thereof Download PDF

Info

Publication number
AU628913B2
AU628913B2 AU48696/90A AU4869690A AU628913B2 AU 628913 B2 AU628913 B2 AU 628913B2 AU 48696/90 A AU48696/90 A AU 48696/90A AU 4869690 A AU4869690 A AU 4869690A AU 628913 B2 AU628913 B2 AU 628913B2
Authority
AU
Australia
Prior art keywords
compound
salt
formula
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU48696/90A
Other languages
English (en)
Other versions
AU4869690A (en
Inventor
Atsushi Akahane
Hirohito Katayama
Takafumi Mitsunaga
Youichi Shiokawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of AU4869690A publication Critical patent/AU4869690A/en
Application granted granted Critical
Publication of AU628913B2 publication Critical patent/AU628913B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU48696/90A 1989-01-23 1990-01-23 Pyrazolopyridine compound and processes for preparation thereof Ceased AU628913B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898901423A GB8901423D0 (en) 1989-01-23 1989-01-23 Pyrazolopyridine compound and processes for preparation thereof
GB8901423 1989-01-23

Publications (2)

Publication Number Publication Date
AU4869690A AU4869690A (en) 1990-07-26
AU628913B2 true AU628913B2 (en) 1992-09-24

Family

ID=10650453

Family Applications (1)

Application Number Title Priority Date Filing Date
AU48696/90A Ceased AU628913B2 (en) 1989-01-23 1990-01-23 Pyrazolopyridine compound and processes for preparation thereof

Country Status (23)

Country Link
US (1) US4985444A (enExample)
EP (1) EP0379979B1 (enExample)
JP (2) JPH0794454B2 (enExample)
KR (1) KR0159502B1 (enExample)
CN (1) CN1031570C (enExample)
AT (1) ATE150462T1 (enExample)
AU (1) AU628913B2 (enExample)
CA (1) CA2008263C (enExample)
DE (1) DE69030206T2 (enExample)
DK (1) DK0379979T3 (enExample)
ES (1) ES2098229T3 (enExample)
FI (1) FI96205C (enExample)
GB (1) GB8901423D0 (enExample)
GR (1) GR3023219T3 (enExample)
HU (2) HUT53368A (enExample)
IE (1) IE900161L (enExample)
IL (1) IL93050A (enExample)
NO (1) NO176356C (enExample)
PH (1) PH30968A (enExample)
PT (1) PT92935B (enExample)
RU (1) RU2007403C1 (enExample)
UA (1) UA43821C2 (enExample)
ZA (1) ZA90200B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU651353B2 (en) * 1990-07-18 1994-07-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and processes for preparation thereof

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338743A (en) * 1988-06-06 1994-08-16 Fujisawa Pharmaceutical Co., Ltd. New use of the adenosine antagonist
US5155114A (en) * 1989-01-23 1992-10-13 Fujisawa Pharmaceutical Company, Ltd. Method of treatment using pyrazolopyridine compound
GB9107513D0 (en) * 1991-04-10 1991-05-29 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
ATE161178T1 (de) * 1992-06-10 1998-01-15 Fujisawa Pharmaceutical Co Pyrazolpyridine für die behandlung der anämie
AU7546794A (en) * 1993-09-06 1995-03-27 Kyowa Hakko Kogyo Co. Ltd. Depression remedy
CN1046724C (zh) * 1993-12-29 1999-11-24 藤泽药品工业株式会社 吡唑并吡啶化合物、含有它们的药物组合物、及其制法与用途
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
RU2172742C2 (ru) * 1995-12-28 2001-08-27 Пфайзер Инк. Стимуляторы секреции гормона роста
DE69731948D1 (de) * 1996-04-25 2005-01-20 Fujisawa Pharmaceutical Co Mittel zur vorbeugung und heilung ischämischer darmlesion und ileus
AUPO111096A0 (en) * 1996-07-18 1996-08-08 Fujisawa Pharmaceutical Co., Ltd. New compound
AU733316B2 (en) * 1996-10-04 2001-05-10 Kyorin Pharmaceutical Co. Ltd. Pyrazolopyridylpyridazinone derivatives and process for preparing the same
EP0972525A4 (en) * 1997-03-18 2000-11-29 Fujisawa Pharmaceutical Co PREVENTIVE AND HEALING AGENTS AGAINST HYPERPHOSPHATEMIA
ATE281458T1 (de) * 1997-09-05 2004-11-15 Glaxo Group Ltd Pharmazeutische zusammensetzung, enthaltend 2,3- diaryl-pyrazolo(1,5-b)pyridazin derivate
AU754094B2 (en) * 1998-06-01 2002-11-07 Astellas Pharma Inc. Remedies for male sterility
WO1999067239A1 (en) * 1998-06-22 1999-12-29 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compounds and medicinal uses thereof
AUPP672198A0 (en) * 1998-10-23 1998-11-19 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
ATE275148T1 (de) 1998-11-03 2004-09-15 Glaxo Group Ltd Pyrazolopyridin derivative als selektive cox-2 inhibitoren
US6541634B2 (en) 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
WO2000052008A1 (en) 1999-02-27 2000-09-08 Glaxo Group Limited Pyrazolopyridines
US20040152659A1 (en) * 1999-05-12 2004-08-05 Fujisawa Pharmaceutical Co. Ltd. Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
AUPQ441499A0 (en) * 1999-12-02 2000-01-06 Fujisawa Pharmaceutical Co., Ltd. Novel compound
GB9930358D0 (en) 1999-12-22 2000-02-09 Glaxo Group Ltd Process for the preparation of chemical compounds
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
AUPQ969800A0 (en) * 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
EP1377573B1 (en) * 2000-12-15 2005-07-27 Glaxo Group Limited Pyrazolopyridine derivatives
ES2245380T3 (es) * 2000-12-15 2006-01-01 Glaxo Group Limited Pirazolopiridinas.
BR0207096A (pt) * 2001-02-20 2004-01-20 Astrazeneca Ab Uso de um composto, compostos, formulação farmacêutica, e, método de tratamento e/ou profilaxia de condições associadas com a inibição de glicogênio sintase quinase-3
US7153855B2 (en) * 2001-03-08 2006-12-26 Smithkline Beecham Corporation Pyrazolopyridinyl pyrimidine therapeutic compounds
WO2002078701A1 (en) * 2001-03-30 2002-10-10 Smithkline Beecham Corporation Use of pyrazolopyridines as therapeutic compounds
EP1372643A1 (en) * 2001-03-30 2004-01-02 Smithkline Beecham Corporation Pyrazolopyridines, process for their preparation and use as therapeutic compounds
JP4219171B2 (ja) * 2001-04-10 2009-02-04 スミスクライン ビーチャム コーポレーション 抗ウイルス性ピラゾロピリジン化合物
BR0209252A (pt) * 2001-04-27 2004-07-20 Eisai Co Ltd Pirazolo[1,5-a]piridinas e medicamentos contendo as mesmas
AU2002305143A1 (en) * 2001-04-27 2002-11-11 Smithkline Beecham Corporation Pyrazolo'1,5-a!pyridine derivatives
US6756498B2 (en) 2001-04-27 2004-06-29 Smithkline Beecham Corporation Process for the preparation of chemical compounds
AUPR548601A0 (en) * 2001-06-06 2001-06-28 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyrazinecompound and pharmaceutical use thereof
KR20040018281A (ko) * 2001-06-21 2004-03-02 스미스클라인 비참 코포레이션 포진 바이러스 감염의 예방 및 치료를 위한 이미다조[1，２－α]피리딘 유도체
ES2286272T3 (es) * 2001-09-07 2007-12-01 Smithkline Beecham Corporation Pirizolo-piridinas para el tratamiento de infecciones por herpes.
US7244740B2 (en) * 2001-10-05 2007-07-17 Smithkline Beecham Corporation Imidazo-pyridine derivatives for use in the treatment of herpes viral infection
AUPR916301A0 (en) * 2001-11-29 2001-12-20 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
WO2003050120A1 (en) * 2001-12-11 2003-06-19 Smithkline Beecham Corporation Pyrazolo-pyridine derivatives as antiherpes agents
US20040021778A1 (en) * 2002-08-05 2004-02-05 Oldani Jerome L. Security system with remote access and control
GB0218876D0 (en) * 2002-08-13 2002-09-25 Merck Sharp & Dohme Therapeutic agents
WO2004033454A1 (en) * 2002-10-03 2004-04-22 Smithkline Beecham Corporation Therapeutic compounds based on pyrazolopyridine derivatives
JP5352452B2 (ja) * 2006-06-06 2013-11-27 メディシノバ， インコーポレイテッド 置換ピラゾロ［１，５−ａ］ピリジン化合物およびその使用方法
KR100809368B1 (ko) * 2006-08-09 2008-03-05 한국과학기술원 성대파를 이용한 음색 변환 시스템
RU2394034C2 (ru) * 2007-04-26 2010-07-10 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН ПРОИЗВОДНЫЕ 4,6-ДИМЕТИЛ-2,3-ДИГИДРО-1Н-ПИРАЗОЛО[4,3-c]ПИРИДИН-3-ОНОВ И ЭФИРЫ 2,6-ДИМЕТИЛ-4-ФЕНИЛ-ГИДРАЗИНОНИКОТИНОВЫХ КИСЛОТ В КАЧЕСТВЕ ПРОМЕЖУТОЧНЫХ ПРОДУКТОВ ДЛЯ ИХ СИНТЕЗА, ОБЛАДАЮЩИЕ АНТИДЕПРЕССАНТНОЙ И АНКСИОЛИТИЧЕСКОЙ АКТИВНОСТЬЮ
MY152687A (en) 2008-04-15 2014-10-31 Eisai R&D Man Co Ltd 3-phenylpyrazolo[5,1-b]thiazole compound
US20110039873A1 (en) * 2009-06-08 2011-02-17 Gaeta Federico C A SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY
AR078521A1 (es) * 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
JPWO2011043387A1 (ja) * 2009-10-08 2013-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロオキサゾール化合物
WO2011074658A1 (ja) 2009-12-18 2011-06-23 田辺三菱製薬株式会社 新規抗血小板薬
SG11201406759YA (en) 2012-04-26 2014-11-27 Bristol Myers Squibb Co Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
ES2640916T3 (es) 2012-04-26 2017-11-07 Bristol-Myers Squibb Company Derivados de imidazotiadiazol e imidazopirazina como inhibidores del receptor 4 activados por proteasa (PAR4) para tratar agregación plaquetaria
KR20150003766A (ko) 2012-04-26 2015-01-09 브리스톨-마이어스 스큅 컴퍼니 혈소판 응집을 치료하기 위한 프로테아제 활성화 수용체 4 (par4) 억제제로서의 이미다조티아디아졸 및 이미다조피리다진 유도체
US9572528B1 (en) 2012-08-06 2017-02-21 Los Angeles Biomedical Research Insitute at Harbor-UCLA Medical Center Monitor for SIDS research and prevention
TWI629982B (zh) * 2013-05-28 2018-07-21 拉夸里亞創藥股份有限公司 多晶型形式
US9617279B1 (en) 2014-06-24 2017-04-11 Bristol-Myers Squibb Company Imidazooxadiazole compounds
US9598419B1 (en) 2014-06-24 2017-03-21 Universite De Montreal Imidazotriazine and imidazodiazine compounds
ES2707124T3 (es) * 2014-08-05 2019-04-02 Raqualia Pharma Inc Derivados de serina como agonistas del receptor de grelina
MX2021011316A (es) * 2019-03-20 2021-10-13 Goldfinch Bio Inc Piridazinonas y metodos de uso de estas.
WO2022071777A1 (ko) * 2020-09-29 2022-04-07 연세대학교 산학협력단 호흡기 질환의 예방 또는 치료용 조성물 및 예방 또는 치료 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587931B2 (en) * 1987-04-01 1989-08-31 Boehringer Mannheim Gmbh Chromogenic compounds, processes for the preparation thereof and the use thereof as enzyme substrates
AU594170B2 (en) * 1986-07-08 1990-03-01 Synthelabo Nitrofuran derivatives, their preparation and compositions containing them
AU605518B2 (en) * 1986-11-26 1991-01-17 Japanese Foundation For Cancer Research Promoting agents of the activity of some antitumor agents against various kinds of tumor cells including multiple drug resistant tumor cells and their synthetic methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5154583A (en) * 1974-11-01 1976-05-13 Kyorin Seiyaku Kk Shinkipirazoro * 1 55a * pirijinjudotaino seizoho
AU556031B2 (en) * 1982-06-16 1986-10-16 May And Baker Ltd. 3-(n,n-dimethylcarbamoyl)pyrazolo(1,5-alpha)-pyridine
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594170B2 (en) * 1986-07-08 1990-03-01 Synthelabo Nitrofuran derivatives, their preparation and compositions containing them
AU605518B2 (en) * 1986-11-26 1991-01-17 Japanese Foundation For Cancer Research Promoting agents of the activity of some antitumor agents against various kinds of tumor cells including multiple drug resistant tumor cells and their synthetic methods
AU587931B2 (en) * 1987-04-01 1989-08-31 Boehringer Mannheim Gmbh Chromogenic compounds, processes for the preparation thereof and the use thereof as enzyme substrates

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU651353B2 (en) * 1990-07-18 1994-07-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and processes for preparation thereof

Also Published As

Publication number Publication date
RU2007403C1 (ru) 1994-02-15
FI96205C (fi) 1996-05-27
KR900011773A (ko) 1990-08-01
US4985444A (en) 1991-01-15
NO900306L (no) 1990-07-24
PT92935A (pt) 1990-07-31
CA2008263C (en) 2000-03-14
EP0379979B1 (en) 1997-03-19
PT92935B (pt) 1995-12-29
GR3023219T3 (en) 1997-07-30
IE900161L (en) 1990-07-23
JPH0794454B2 (ja) 1995-10-11
GB8901423D0 (en) 1989-03-15
CA2008263A1 (en) 1990-07-23
JPH02243689A (ja) 1990-09-27
KR0159502B1 (ko) 1998-12-01
HU211684A9 (en) 1995-12-28
JPH0881465A (ja) 1996-03-26
IL93050A0 (en) 1990-11-05
EP0379979A1 (en) 1990-08-01
FI900307A0 (fi) 1990-01-19
FI96205B (fi) 1996-02-15
ATE150462T1 (de) 1997-04-15
AU4869690A (en) 1990-07-26
NO176356B (no) 1994-12-12
DE69030206T2 (de) 1997-07-10
UA43821C2 (uk) 2002-01-15
NO176356C (no) 1995-03-22
DE69030206D1 (de) 1997-04-24
IL93050A (en) 1995-05-26
HUT53368A (en) 1990-10-28
DK0379979T3 (enExample) 1997-04-07
CN1031570C (zh) 1996-04-17
NO900306D0 (no) 1990-01-22
ZA90200B (en) 1990-10-31
HU900228D0 (en) 1990-03-28
PH30968A (en) 1997-12-23
CN1044656A (zh) 1990-08-15
ES2098229T3 (es) 1997-05-01

Similar Documents

Publication Publication Date Title
CA2008263C (en) Pyrazolopyridine compound and processes for preparation thereof
US5155114A (en) Method of treatment using pyrazolopyridine compound
AU651353B2 (en) Pyrazolopyridine compound and processes for preparation thereof
EP0370381B1 (en) 2(1H)-quinolinone compounds, processes for the preparation thereof and pharmaceutical composition comprising the same
AU694157B2 (en) Pyrazolopyridine adenosine antagonists
SK199592A3 (en) Heterocycylic compounds, their manufacture and use
CA1309095C (en) Aminoimidazoquinoline derivatives
EP0636626A1 (en) Pyrazolopyrimidine Derivatives
JPH04346978A (ja) ベンズイミダゾール類及びこれらの化合物を含有する薬剤組成物
US5354759A (en) Angiotenin II antagonizing heterocyclic compounds
MXPA06014699A (es) Derivados de pirazolo-piridina.
EP1606280A2 (en) Tetrahydropyranyl cyclopentyl heterocylic amide modulators of chemokine receptor activity
KR20250023365A (ko) 알파 4 베타 7 인테그린 조정제 및 그의 용도
AU597190B2 (en) Therapeutic agents
US20090298872A1 (en) Compounds and compositions as modulators of steroidal receptors and calcium channel activities
JPH10513172A (ja) ５−ｈｔ▲下１ｄ▼受容体アゴニストとしての置換１，４−ピペラジン−ヘテロアリール誘導体
EP0553682A1 (en) Imidazo 4,5-b pyridine derivatives as Angiotensin II antagonists
KR20060092219A (ko) 유도성 ｎｏ-합성효소 억제제로서의 아미노피리딘-유도체
EP1915373B1 (en) Heterobicyclic compounds useful as p38 kinase inhibiting agents
US5348960A (en) Imidazo[4,5-b]quinolinyl oxy alkyl tetrazolyl piperidine derivatives
JPS59141580A (ja) インド−ル誘導体
CA2631794A1 (en) P38 kinase inhibiting agents

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired